Dioseve Inc., a Tokyo, Japan-based developer of assisted reproductive technology using oocytes derived from iPS cells, raised USD7m in funding.
Backers included Spiral Capital, Archetype Ventures, ANRI, ASKA Pharmaceutical Co., DG Daiwa Ventures, Future Venture Capital Co., QR Investment, and other two investors. With this round, the total funds raised to date amount to approximately USD10m.
The company intends to use the funds to advance research and development and expand the workforce for global expansion.
Established in 2021 and led by CEO Kazuma Kishida, Dioseve is involved in the development of a pipeline providing a new infertility treatment using the “DIOLs” technology. This method involves introducing specific genes into iPS cells to produce oocytes in a short period, without expensive growth factors or advanced techniques required by existing production methods, enabling oocyte production in cheap and large quantities.
FinSMEs
09/07/2024